Lung cancer uses cunning mechanisms to evade the immune system. Can new antibody therapies outwit the disease?
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
|
After 20 years of treating lung cancer, and 20 years of dashed hopes in lung-cancer immunotherapy, there is finally a glimmer of hope in both vaccines and non-vaccine immunotherapies, such as the PD-1 and PD-L1 inhibitors.
If the past decades of failure have taught the industry anything, it is that early trial success rarely leads to a breakthrough drug. Phase III trial data from the checkpoint inhibitors and the vaccines are eagerly awaited.
Open access
NATURE | OUTLOOK
Immunotherapy: Chemical tricksBianca NogradyNature 513, S10–S11 (11 September 2014) doi:10.1038/513S10aPublished online 10 September 2014